
Journal of Prevention and Treatment for Stomatological Diseases ›› 2019, Vol. 27 ›› Issue (9): 545-550.doi: 10.12016/j.issn.2096-1456.2019.09.001
• Expert Forum • Previous Articles Next Articles
CLC Number:
[1] | Mirabello L, Scd R, Sharon A , et al. Osteosarcoma incidence and survival rates from 1973 to 2004[J]. Cancer, 2009,115(7):1531-1543. |
[2] | Caron AS, Hajdu S, Strong EW . Osteogenic sarcoma of the facial and cranial bones: a review of forty-three cases[J]. Am J Surg, 1971,122(6):719-725. |
[3] | Chen YM, Gokavarapu S, Shen QC , et al. Chemotherapy in head and neck osteosarcoma: adjuvant chemotherapy improves overall survival[J]. Oral Oncol, 2017,73:124-131. |
[4] | Chen YM, Shen QC, Gokavarapu S , et al. Osteosarcoma of head and neck: a retrospective study on prognostic factors from a single institute database[J]. Oral Oncol, 2016,58:1-7. |
[5] | 李江, 何荣根 . 颌面部骨肉瘤61例临床病理研究[J]. 中华口腔医学杂志, 2003,38(6):444-446. |
[6] | 李晓, 季彤 . 颌面头颈部骨肉瘤化学治疗的研究进展[J]. 国际口腔医学杂志, 2017,44(1):83-86. |
[7] | Gazitt Y, Kolaparthi V, Moncada K , et al. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways[J]. Int J Oncol, 2009,34(2):551-561. |
[8] | Smith RB, Apostolakis LW, Karnell LH , et al. National cancer data base report on osteosarcoma of the head and neck[J]. Cancer, 2003,98(8):1670-1680. |
[9] | Lau CC . Molecular classification of osteosarcoma[J]. Cancer Treat Res, 2009,152:459-465. |
[10] | Gorlick R . Current concepts on the molecular biology of osteosarcoma[J]. Cancer Treat Res, 2009,152:467-478. |
[11] | 丘钜世, 朱全胜, 王连唐 . 骨肉瘤的病理类型及其病理特点[J]. 中华病理学杂志, 1997,26(5):259-261. |
[12] | Green D, Mohorianu I, Mcnamara I , et al. miR-16 is highly expressed in paget’s associated osteosarcoma[J]. Endocr Relat Cancer, 2017,24(5):27-31. |
[13] | Lie LQ, Liao, Hong HH , et al. Radiation-induced osteosarcoma of the maxilla and mandible after radiotherapy for nasopharyngeal carcinoma[J]. Chin J Cancer, 2016,35(11):625-631. |
[14] | 王春彦, 杨晨, 李叔强 , 等. 外伤性骨肉瘤病例报道1例及相关文献回顾[J]. 中国骨伤, 2014,27(1):69-70. |
[15] |
张景峰, 王跃 . WHO骨肿瘤分类第四版解读与比较[J]. 中华骨科杂志, 2015,35(9):975-979.
doi: 10.3760/cma.j.issn.0253-2352.2015.09.014 |
[16] | Hasrayati A, Ita A, Afiati A , et al. The role of osteocalcin and alkaline phosphatase immunohistochemistry in osteosarcoma diagnosis[J]. Patholog Res Int, 2018, Doi: 10.1155/2018/6346409. |
[17] | Koehne AL, Sayles LC, Breese MR , et al. Abstract a35: characterization of the genomic landscape of osteosarcoma metastasis[J]. Cancer Res, 2016,76(5):35. |
[18] | 方三高, 马强, 杜娟 , 等. 高级别表面骨肉瘤临床病理分析并文献复习[J]. 现代肿瘤医学, 2018,26(9):1431-1436. |
[19] | 袁俊清, 张惠箴, 黄文涛 , 等. 骨肉瘤诊断及预后相关分子标志物的研究进展[J]. 中华病理学杂志, 2014,43(6):422-424. |
[20] | Inoue T, Hagiyama M, Enoki E , et al. Cell adhesion molecule 1 is a new osteoblastic cell adhesion molecule and a diagnostic marker for osteosarcoma[J]. Life Sci, 2013,92(1):91-99. |
[21] | Nedelcu T, Kubista B, Koller A , et al. Livin and Bcl-2 expression in high-grade osteosarcoma[J]. J Cancer Res Clin Oncol, 2008,134(2):237-244. |
[22] | Yang QC, Zeng BF, Shi ZM , et al. Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma[J]. J Exp Clin Cancer Res, 2006,25(4):593-599. |
[23] | National Comprehensive Cancer Network. NCCN guideline for bone cancer. Version 1[Z]. 2019: 20-25. |
[24] | 张陈平 . 口腔癌的间室外科[ C]//国际暨全国头颈肿瘤学术大会会议论文集, 2011. |
[25] | National Comprehensive Cancer Network. NCCN soft tissue sarcoma, Version 2[Z]. 2018: 51. |
[26] | Smith RB, Apostolakis LW, Karnell LH . et al. National cancer data base report on osteosarcoma of the head and neck[J]. Cancer, 2003,98(8):1670-1680. |
[27] | Oertel S, Blattmann C, Rieken S , et al. Radiotherapy in the treatment of primary osteosarcoma -- a single center experience[J]. Tumori, 2010,96(4):582-588. |
[28] | Guadagnolo BA, Zagars GK, Raymond KA , et al. Osteosarcoma of the jaw/craniofacial region outcomes after multimodality treatment[J]. Cancer, 2009,115(14):3262-3270. |
[29] | Zhang W, Tanaka M, Sugimoto Y , et al. Carbon-ion radiotherapy of spinal osteosarcoma with long-term follow[J]. 2016,25(1):113-117. |
[30] | Deutsch M, Tersak JM . Radiotherapy for symptomatic metastases to bone in children[J]. Am J Clin Oncol, 2004,27(2):128-131. |
[31] | 陆嘉德, 孔琳, 高晶 , 等. 质子重离子放射治疗的临床研究概况[J]. 中华放射医学与防护杂志, 2016,36(8):611-615. |
[32] | Kong L, Hu J, Gao J , et al. Particle radiation therapy of head and neck malignancies at the Shanghai Proton and Heavy Ion Center[J]. IJROBP, 2018,100(5):1403. |
[33] | Mücke T, Mitchell DA, Tannapfel A , et al. Effect of neoadjuvant treatment in the management of osteosarcomas of the head and neck[J]. J Cancer Res Clin Oncol, 2014,140(1):127-131. |
[34] | Sakamoto A, Iwamoto Y . Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy[J]. Rev Recent Clin Trials, 2008,3(3):228-231. |
[35] | Gill J, Ahluwalia MK, Geller D , et al. New targets and approaches in osteosarcoma[J]. Pharmacol Ther, 2013,137(1):89-99. |
[36] | Meyers PA, Schwartz CL, Krailo MD , et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children’s Oncology Group[J]. J Clin Oncol, 2008,26(4):633-638. |
[37] | Anninga JK, Gelderblom H, Fiocco M , et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?[J]. Eur J Cancer, 2011,47(16):2431-2445. |
[38] | Patel S, Delaney TF . Advanced-technology radiation therapy for bone sarcomas[J]. Cancer Control, 2008,15(1):21-37. |
[39] | Daw NC, Neel MD, Rao BN , et al. Frontline treatment of localized osteosarcoma without methotrexate[J]. Cancer, 2011,117(12):2770-2778. |
[40] | Granowski-Lecornu M, Chuang SK, Kaban LB , et al. Osteosarcoma of the jaws: factors influencing prognosis[J]. J Oral Maxillofac Surg, 2011,69(9):2368-2375. |
[41] | Thariat J, Julieron M, Brouchet A , et al. Osteosarcomas of the mandible: are they different from other tumor sites?[J]. Crit Rev Oncol Hematol, 2012,82(3):280-295. |
[42] | Thariat J, Schouman T, Brouchet A , et al. Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult--a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE[J]. Ann Oncol, 2013,24(3):824-831. |
[43] | Smithey BE, Pappo AS, Hill DA . C-kit expression in pediatric solid tumors -- a comparative immunohistochemical study[J]. 2002,26(4):486-492. |
[44] | Wilhelm SM, Carter C, Tang L , et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res, 2004,64(19):7099-7109. |
[45] | Grignani G, Palmerini E, Dileo P , et al. A phase Ⅱ trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study[J]. Ann Oncol, 2012,23(2):508-516. |
[46] | Coventon J . A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma[J]. Bone Oncol, 2017,8(8):4-7. |
[47] | Graaf WD, Jean-Yves B, Chawla SP , et al. Pazopanib for metastatic soft-tissue sarcoma(PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet, 2012,379(9829):1879-1886. |
[48] | Safwat A, Boysen A, Lucke A , et al. Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients[J]. Acta Oncol (Madr), 2014,53(10):1451-1454. |
[49] | Walcott BP, Nahed BV, Mohyeldin A , et al. Chordoma: current concepts, management, and future directions[J]. Lancet Oncol, 2012,13(2):e69-e76. |
[50] | Topalian SL, Brahmer JR, Hodi F , et al. Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: clinical activity, safety, and a potential biomarker for response[J]. J Clin Oncol, 2012,30(15):2509. |
[51] | Riley JL . PD-1 signaling in primary T cells[J]. Immunol Rev, 2009,229(1):114-125. |
[52] | Lussier DM, Johnson JL, Hingorani P , et al. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma[J]. J Immunother Cancer, 2015,3(3):21. |
[53] | Shih K, Arkenau HT, Infante JR . Clinical impact of checkpoint inhibitors as novel cancer therapies[J]. Drugs, 2014,74(17):1993-2013. |
[54] | Koirala P, Roth M, Gill J , et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma[J]. Cancer Res, 2016,76(14):30093. |
[1] | LI Xiaodong,MENG Jian. Application progress of recombinant human endostatin in the treatment of head and neck cancer [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(4): 267-272. |
[2] | WANG Yueyang,ZHANG Lili,ZHOU Weiwei,WANG Nan. Retrospective study of flexible fiber splints in the treatment of horizontal root fractures in permanent teeth [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(3): 163-168. |
[3] | YUAN Kaifang,CHEN Weiliang,ZHOU Bin,ZHANG Daming. Comparison of the clinical effect of a facial-submental artery island flap in reconstruction after resection of oral cavity and oropharyngeal squamous cell carcinoma [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(2): 84-87. |
[4] | LI Ruichun,JING Kaian,WANG Lina,MA Rui,JING Jie,MA Jian. Malformation of Wharton′s duct with multiple sialoliths: a case report and literature review [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(2): 93-96. |
[5] | WANG Songling,DOU Huixin,QIN Lizheng,LI Hua. The etiology, diagnosis and treatment of sialorrhea [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(8): 477-484. |
[6] | TAO Qian,LIANG Peisheng. Evolution of diagnostic criteria for Sjögren′s Syndrome [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(5): 273-279. |
[7] | ZHANG Ning,HU Yue,QIAO Chunyan,JI Xin,HAN Ruyu,SUN Lanfang,LI Minghe,HAN Chengmin. Mucoepidermoid carcinoma arising in Warthin’s tumor of the upper lip: a case report and review [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(4): 250-254. |
[8] | GUO Xiao,DU Xinmei,CHENG Lei,ZHOU Xuedong,LI Mingyun. Research progress on the function and metabolism of d-alanine in bacteria [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(4): 264-267. |
[9] | HE Yue,LI Xiaoguang. Prevention and treatment of osteoradionecrosis of the jaws [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(3): 143-152. |
[10] | LI Song,SU Rugan. Application of digital technology in orthodontic clinic [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(2): 69-73. |
[11] | BUHAILIQIGULI Maimaitituersun,PATIGULI Wusiman,ADILI Moming. Peripheral primitive neuroectodermal tumor of the mandible: a case report and literature review [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(12): 784-787. |
[12] | CHEN Zengquan,JIN Tingting,WANG Yan,WANG Lin,MAI Lianxi,HUANG Zhiquan. Sclerosing polycystic adenosis of the parotid gland: a case report and literature review [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(11): 729-732. |
[13] | LU Weiying,LIU Ping,CHEN Jiawei,LIU Shuying,XU Pingping. Effects of X-ray irradiation on proliferation and RANTES expression of the mouse osteogenic precursor cell line MC3T3-E1 [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(10): 621-626. |
[14] | Zhirong WU, Shiguang Huang. Research progress on the etiology, clinical examination and treatment of peri-implantitis [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(6): 401-405. |
[15] | Qian TAO, Xin LIU. Salivary transcriptomics and biomarkers of oral squamous cell carcinoma [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(4): 211-217. |
|